卡瑞利珠单抗联合吉西他滨+顺铂化疗在晚期肺鳞癌患者中的效果观察

doi:10.3969/j.issn.1007-3205.2024.12.006

河北医科大学学报 ›› 2024, Vol. 45 ›› Issue (12): 1394-1398.doi: 10.3969/j.issn.1007-3205.2024.12.006

卡瑞利珠单抗联合吉西他滨+顺铂化疗在晚期肺鳞癌患者中的效果观察

1.东部战区总医院秦淮医疗区呼吸内科，江苏南京 620002；2.东部战区总医院秦淮医疗区体检中心，江苏南京 620002

出版日期:2024-12-25 发布日期:2025-01-03
作者简介:张文娟（1983-），女，江西鹰潭人，东部战区总医院秦淮医疗区主治医师，医学学士，从事呼吸科危重症疾病及肺癌诊治研究。
基金资助:
江苏省科技计划项目(面上基金项目)(BE2019719)

Observation of the efficacy of camrelizumab combined with gemcitabine and cisplatin chemotherapy in patients with advanced squamous cell lung cancer

1.Department of Respiratory Medicine, Qinhuai Medical Area, General Hospital of Eastern Theater
Command, Jiangsu Province,Nanjing 620002, China; 2.Physical Examination Center,
Qinhuai Medical Area, General Hospitalof Eastern Theater Command,
Jiangsu Province, Nanjing 620002, China

Online:2024-12-25 Published:2025-01-03

摘要/Abstract

摘要： 目的探究卡瑞利珠单抗联合吉西他滨+顺铂化疗在晚期肺鳞癌患者中的治疗效果。
方法将82例晚期肺鳞癌患者根据治疗方案分为2组，其中对照组38例，予以吉西他滨+顺铂化疗，观察组44例，在对照组基础上联合卡瑞利珠单抗治疗。治疗2个周期后，评价2组的短期疗效、药物毒性反应、肿瘤标志物表达［鳞状细胞癌抗原（squamous cell carcinoma antigen，SCC-Ag）、角蛋白19片段抗原（cytokeratin 19 fragment antigen，CYFRA）21-1、甲状腺转录因子1（thyroid transcription factor-1，TTF-1）］，随访12个月，记录患者的中位生存率（overall survival，OS）和中位无进展生存期（progression-free survival，PFS）。
结果观察组的客观缓解率为29.55%，高于对照组10.53%；疾病控制率为77.27%，高于对照组52.63%（P＜0.05）。治疗后，2组的血清SCC-Ag、CYFRA21-1较治疗前均降低，观察组低于对照组（P＜0.05）；2组治疗后的TTF-1水平比较差异无统计学意义（P＞0.05）。2组的骨髓抑制、消化道反应、肝功能异常、皮肤黏膜毒性、过敏反应、神经系统毒性发生率比较差异无统计学意义（P＜0.05）。观察组和对照组的中位PFS分别4个月、3个月，中位OS分别为11个月、7个月。2组的PFS和OS生存曲线比较差异均有统计学意义（Log-rank χ2=9.937、12.471，P＜0.05）。
结论卡瑞利珠单抗联合吉西他滨+顺铂化疗治疗晚期肺鳞癌，有助于提升患者的抗肿瘤效果，调节肿瘤相关生物学标志物的表达，安全性良好。

关键词: 肺肿瘤, 吉西他滨, 顺铂, 卡瑞利珠单抗

Abstract: Objective To explore the efficacy of carilizumab combined with gemcitabine and cisplatin chemotherapy in patients with advanced lung squamous cell carcinoma (LSCC).
Methods In total, 82 patients with advanced LSCC were divided into two groups according to the treatment plan. The control group consisted of 38 patients who received gemcitabine and cisplatin chemotherapy, while the observation group consisted of 44 patients who received treatment with combination therapy of carizolizumab on the basis of the control group. After 2 cycles of treatment, the short-term efficacy, drug toxicity, and tumor marker expression ［squamous cell carcinoma antigen (SCC Ag), cytokeratin 19 fragment antigen (CYFRA) 21-1, thyroid transcription factor-1 (TTF -1)］ of both groups were evaluated. They were followed up for 12 months, and the median overall survival (OS) and progression-free survival (PFS) of the patients were recorded.
Results The objective remission rate of the observation group was 29.55%, which was higher than that of the control group (10.53%), and the disease control rate was 77.27%, which was higher than that of the control group (52.63%) (P＜0.05). After treatment, the serum levels of SCC Ag and CYFRA21-1 in both groups decreased compared with those before treatment, which were lower in the observation group than in the control group (P＜0.05). There was no significant difference in TTF-1 levels between the two groups after treatment (P＞0.05). There was no significant difference in the incidence of bone marrow suppression, gastrointestinal reactions, liver dysfunction, skin and mucosal toxicity, allergic reactions, and neurological toxicity between the two groups (P＜0.05). The median PFS of the observation group and the control group were 4 months and 3 months, respectively, and the median OS was 11 months and 7 months, respectively. The difference in PFS and OS survival curves between the two groups was statistically significant (Log rank χ2=9.937, 12.471, P＜0.05).
Conclusion The combination of carilizumab and gemcitabine+cisplatin chemotherapy for advanced LSCC can improve the anti-tumor effect of patients, regulate the expression of tumor-related biomarkers, and has good safety.

Key words: lung neoplasms, gemcitabine, cisplatin, carilizumab

张文娟1, 路东明1, 艾月琴1, 承晓梅2. 卡瑞利珠单抗联合吉西他滨+顺铂化疗在晚期肺鳞癌患者中的效果观察 [J]. 河北医科大学学报, 2024, 45(12): 1394-1398.

ZHANG Wen-juan1, LU Dong-ming1, AI Yue-qin1, CHENG Xiao-mei2. Observation of the efficacy of camrelizumab combined with gemcitabine and cisplatin chemotherapy in patients with advanced squamous cell lung cancer [J]. Journal of Hebei Medical University, 2024, 45(12): 1394-1398.

[1]	黄语嫣1, 邓太兵2, 庞敏1, 姜永杰1, 蒋莉1. 肺结节良恶性概率预测模型的建立与验证 [J]. 河北医科大学学报, 2024, 45(3): 278-283.
[2]	王嘉欣1, 张俊萍2（综述）, 崔文芳1, 李丽1（审校）. 肺癌微环境中巨噬细胞的作用及免疫治疗机制 [J]. 河北医科大学学报, 2024, 45(3): 308-312.
[3]	龚海鹏, 王飞. 右美托咪定复合罗哌卡因行竖脊肌平面阻滞对胸腔镜肺癌手术患者镇痛效果、炎症应激及认知功能的影响 [J]. 河北医科大学学报, 2024, 45(11): 1289-1294.
[4]	张敏, 梁正, 李朝玉. 不同氧浓度肺复张对肺癌术患者的影响及肺部并发症Probit归因分析[J]. 河北医科大学学报, 2023, 44(9): 1074-1079.
[5]	徐海丽, 陈虹烨, 佟飞, 孔明健. 单次多点与连续胸椎旁神经阻滞在单侧开胸术围术期镇痛效果及安全性比较[J]. 河北医科大学学报, 2022, 43(3): 335-338，344.
[6]	王雪萍, 张红玉, 陈海明. 七氟烷麻醉对老年肺癌患者术后血清IL-1、ICAM-1表达及肺部并发症的影响[J]. 河北医科大学学报, 2021, 42(9): 1084-1088.
[7]	王东昌, 李亚华（综述）, 邵娟, 陈刚（审校）. 肺癌发生骨转移的机制进展[J]. 河北医科大学学报, 2021, 42(3): 358-362.
[8]	豆振京，乔玉华*，郭荣，杨丽晖，崔剑，郝强. 吉西他滨灌注联合经尿道钬激光切除术对浅表性膀胱癌患者血清CXCL5及尿NMP22水平的影响[J]. 河北医科大学学报, 2020, 41(7): 784-787,823.
[9]	韩丽娜1，孙楠1，王珊1，赵莎2，周欣亮3，赵学涛1*. 血小板输注对晚期肺癌患者血清中MMP-9、MMP-2及VEGF水平的影响[J]. 河北医科大学学报, 2020, 41(6): 676-679.
[10]	刘玉芳1，高欣1，李玉琢2，牛志坤1，何会娜1，薛娜娜3*. 人文护理对肺癌患者生活质量的影响#br#[J]. 河北医科大学学报, 2020, 41(4): 470-473.
[11]	穆卫红，陈文琪，彭园园，张静*. miR-141-3p表达与卵巢癌细胞顺铂化疗敏感性的相关性研究[J]. 河北医科大学学报, 2020, 41(2): 167-171.
[12]	邓皓文1，汪志宇2，刘亮3，吴瑞峰4，李超5，王雷1*. 沉默PLK1基因表达对肺腺癌H1792细胞肿瘤生物学行为影响的研究[J]. 河北医科大学学报, 2019, 40(11): 1246-1250.
[13]	刘〓颖1，王泽阳2，任文君2，刘丽华1，侯志华1，刘欣燕1*. 脂质体紫杉醇与吉西他滨联合顺铂治疗肺癌肝转移的效果比较[J]. 河北医科大学学报, 2018, 38(7): 810-812,821.
[14]	单新洁1，祁晓婷2，俞〓荣1，王〓丽1*. 4项血清肿瘤标志物联合检测在肺癌中的应用价值分析[J]. 河北医科大学学报, 2018, 38(7): 833-837.
[15]	赵志芳1，李旭泽2，赵云霞1，李亚华1，王东昌1，陈〓刚1*. 降钙素原、C反应蛋白鉴别肺癌患者肿瘤热与感染性发热的价值[J]. 河北医科大学学报, 2018, 38(5): 500-503.

卡瑞利珠单抗联合吉西他滨+顺铂化疗在晚期肺鳞癌患者中的效果观察

Observation of the efficacy of camrelizumab combined with gemcitabine and cisplatin chemotherapy in patients with advanced squamous cell lung cancer

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价